Enhanced geothermal has had a promising few years, nudged forward by data centers’ insatiable demand for electricity. Fervo Energy has landed deals on those tailwinds, suggesting, but not guaranteeing, that the company was through the “valley of death.” The term describes when a startup has proven its tech, but hasn’t raised enough money to show it can work profitably at scale. Many startups fail to ever move past this point, and end up dying off. Exactly when a startup emerges from the valley of deat ...

Core Insights - The biotech industry is highly competitive, particularly in the area of advanced therapeutic medicinal products (ATMPs), requiring companies to distinguish themselves to attract investor capital [1] - Despite challenges, investor engagement remains strong, with a reported 70.9% increase in total venture financing deal value from Q2 to Q3 2025 [2] - A survey indicates that 39% of industry respondents are optimistic about biotech funding recovery in the next year, a 24% increase from May 2025 [3] Investment Considerations - Investors prioritize companies with solid data addressing unmet medical needs, emphasizing the importance of data in reducing risk and enhancing company value [5] - A robust data package and a strong intellectual property (IP) strategy are critical factors for attracting investment [6] - Companies should strategically position themselves based on their data package and differentiate from competitors and previous failures in the market [7] - Identifying the latest developments in the industry and using relevant positive controls can help investors understand how a new drug compares to existing standards of care [8]